Method of detecting fetal chromosomal aneuploidy
11710565 · 2023-07-25
Assignee
Inventors
- Sun Shin Kim (Yongin-si, KR)
- Myung Jun Jeong (Suwon-si, KR)
- Kyung Tae Min (Suwon-si, KR)
- Min Ae An (Yongin-si, KR)
- Jung Su Ha (Suwon-si, KR)
- So Ra Lee (Suwon-si, KR)
- Jin Han Bae (Suwon-si, KR)
- Hee Jae Joo (Yongin-si, KR)
Cpc classification
G16B40/00
PHYSICS
G16B50/00
PHYSICS
G16B20/20
PHYSICS
G16H50/20
PHYSICS
G06F17/18
PHYSICS
C12Q1/6806
CHEMISTRY; METALLURGY
G16H50/30
PHYSICS
G16B20/00
PHYSICS
International classification
G16H50/20
PHYSICS
G16B20/00
PHYSICS
G16B30/00
PHYSICS
G16B20/20
PHYSICS
G16H50/30
PHYSICS
G16B40/00
PHYSICS
G16B50/00
PHYSICS
C12Q1/6806
CHEMISTRY; METALLURGY
Abstract
Provided are a method of detecting chromosomal aneuploidy of a targeted fetal chromosome, and a computer-readable medium having recorded thereon a program to be applied to performing the method. According to the present disclosure, fetal chromosomal aneuploidy may be non-invasively and prenatally diagnosed with excellent sensitivity and specificity.
Claims
1. A method of detecting chromosomal aneuploidy of a target fetal chromosome in a test sample using a massively parallel sequencing system, the method comprising: isolating a plurality of nucleic acid fragments from a biological sample of a pregnant woman including fetal nucleic acid fragments as the test sample; obtaining sequence information (reads) of the plurality of nucleic acid fragments by performing massively parallel sequencing of the plurality of nucleic acid fragments using a massively parallel sequencing system; mapping the reads obtained using the massively parallel sequencing system to a reference human genome to assign the reads of the plurality of the nucleic acid fragments to the target fetal chromosome; calculating a GC content and a fraction of reads (Rf) of the plurality of the nucleic acid fragments on the target fetal chromosome to the number of the nucleic acid fragments, based on the reads of the plurality of the nucleic acid fragments assigned to the chromosome; selecting adaptive reference samples belonging to a shared range of unit values of Rf and unit values of GC content from reference samples, based on the calculated Rf and GC content on the target chromosome; calculating z scores of verification reference samples and a z score of the test sample using the selected adaptive reference samples; determining that the target chromosome has chromosomal aneuploidy when, by comparing the calculated z scores of the verification reference samples with the z score of the test sample, the z score of the test sample is larger than the z scores of the verification reference samples; and performing an invasive method selected from chorionic villus sampling, amniocentesis, and sampling from an umbilical cord, based on the determining that the target chromosome has chromosomal aneuploidy, wherein the selected adaptive reference samples have a lower coefficient of variance than reference samples without adaptive selection.
2. The method of claim 1, wherein the biological sample is blood, plasma, serum, urine, saliva, mucus, sputum, feces, tears, or a combination thereof.
3. The method of claim 1, further comprising excluding intervals with a low confidence level for reads from subjects of analysis by examining depth distribution of the reads of the nucleic acid fragments assigned to the chromosome at each interval, after assigning the reads of the nucleic acid fragments to the chromosome.
4. The method of claim 3, wherein the interval is an interval set in units of about 5 kb to about 50 kb.
5. The method of claim 3, wherein the excluding of intervals with a low confidence level for the reads from subjects of analysis comprises removing mismatches, removing multi-mapped reads, removing duplicated reads, or a combination thereof.
6. The method of claim 1, further comprising performing locally weighted scatterplot smoothing (LOWESS or LOESS) regression analysis of the reads of the nucleic acid fragments according to the following Equation 1 to reduce GC content bias, after assigning the reads of the nucleic acid fragments to the chromosome:
Rf.sub.ij′=RC.sub.ij/Σ.sub.j=1.sup.22RC.sub.ij (Equation 1) wherein Rfij′ represents a corrected fraction of reads on chromosome j in sample i, and RCij represents a corrected number of unique reads on chromosome j in sample i.
7. The method of claim 1, further comprising performing normalization of the reads of the nucleic acid fragments according to the following Equation 2, after assigning the reads of the nucleic acid fragments to the chromosome:
Rf.sub.i′j′=Rf.sub.ij′/Σ.sub.i=1.sup.NRf.sub.ij′ (Equation 2) wherein Rfi′j′ represents a normalized fraction of reads on chromosome j in sample i, and N represents the total number of samples.
8. The method of claim 1, wherein the reference sample are obtained from a biological sample of a pregnant woman carrying a euploid fetus.
9. The method of claim 1, further comprising establishing a linear regression model from all of the reference samples.
10. The method of claim 1, further comprising extending the unit values of Rf of the reference samples according to Rf values of the test samples, extending the unit values of GC of the reference samples according to GC contents of the test samples, or a combination thereof.
11. The method of claim 1, wherein the calculating of z scores of the verification reference samples and z scores of the test samples comprises performing a linear regression analysis according to the following Equation 3 and calculating a linear predicted value of Rf according to the following Equation 4:
Rf.sub.i′j′=α+β×GC.sub.i′j′+e (Equation 3) Wherein, in Equation 3, Rfi′j′ represents a normalized fraction of reads on chromosome j in sample i, α represents a constant, β represents a coefficient factor between GC content and Rf, and e represents a residual (R); and
Rf′.sub.i′j′=α+β×GC.sub.i′j′ (Equation 4) in Equation 4, Rfi′j′ represents a fitted predicted value of a fraction of reads on chromosome j in sample i, α represents a constant, and β represents a coefficient factor between GC content and Rf.
12. The method of claim 11, wherein the calculating of z scores of the verification reference samples and z scores of the test samples comprises calculating a residual (R) from a calculated value from the linear regression analysis and the calculated linear predicted value according to the following Equation 5, and calculating a Z score from the calculated residual according to the following Equation 6:
R=Rf.sub.i′j′−Rf′.sub.i′j′ (Equation 5); and
z score=(R−R′)/σ′ (Equation 6) wherein, in Equation 6, R′ represents a mean value of a residual of an adaptive reference sample, R represents a residual value of a test sample, and a′ represents a standard deviation of the residual of the adaptive reference sample.
13. The method of claim 1, further comprising selecting reference samples belonging to GC content±unit value of the target chromosome or GC content±unit value of the adaptive reference samples, as verification samples; calculating z scores of the verification samples; and verifying that the target chromosome has chromosomal aneuploidy by comparing the calculated z scores of the verification samples with the z scores of the test samples.
14. The method of claim 1, wherein the target chromosome is chromosome 13, chromosome 18, chromosome 21, an X chromosome, a Y chromosome, or a combination thereof.
15. The method of claim 1, wherein the chromosomal aneuploidy is trisomy 13, trisomy 18, trisomy 21, XO, XXX, XXY, XYY, or a combination thereof.
16. A system containing a computer-readable medium having recorded thereon a program that performs the steps of: mapping reads obtained from massively parallel sequencing of a plurality of nucleic acid fragments isolated from a biological sample of a pregnant woman including fetal nucleic acid fragments as a test sample to a reference human genome to assign the reads of the plurality of the nucleic acid fragments to a target chromosome, wherein the massively parallel sequencing was performed using a massively parallel sequencing system; calculating a GC content and a fraction of reads (Rf) of the plurality of the nucleic acid fragments on the target chromosome to the number of the nucleic acid fragments, based on the reads of the plurality of the nucleic acid fragments assigned to the chromosome; selecting adaptive reference samples belonging to a shared range of unit values of Rf and unit values of GC content from reference samples, based on the calculated Rf and GC content on the target chromosome; calculating z scores of verification reference samples and a z score of the test sample using the selected adaptive reference samples; and determining that the target chromosome has chromosomal aneuploidy when, by comparing the calculated z scores of the verification reference samples with the z score of the test sample, the z score of the test sample is larger than the z scores of the verification reference samples; wherein the selected adaptive reference samples have a lower coefficient of variance than reference samples without adaptive selection; and wherein the result obtained by determining that the target chromosome has chromosomal aneuploidy is used to avoid performing an invasive method selected from chorionic villus sampling, amniocentesis, and sampling from an umbilical cord, based on the determining that the target chromosome has chromosomal aneuploidy.
Description
BRIEF DESCRIPTION OF DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
MODE OF DISCLOSURE
(10) Hereinafter, the present disclosure will be described in more detail with reference to Examples. However, these Examples are for illustrative purposes only, and the scope of the present disclosure is not intended to be limited by these Examples.
Example 1. Non-Invasive Detection of Fetal Chromosomal Aneuploidy
(11) 1. Preparation of Sample
(12) A total of 447 pregnant women were enrolled at 12 hospitals in Korea. Information of the test subjects is shown in Table 1 below.
(13) TABLE-US-00001 TABLE 1 Characteristic Value No. of pregnant women 447 Maternal age (year) Mean 35 Range 20 to 46 Gestational age (week) Mean 15 Median 16 Range 11 to 22 Pregnancy trimester (%) First: 1-13 week gestation 137 (30.6) Second: 14-26 week gestation 310 (69.4) Third: 27-40 week gestation 0 Fetal sex (%) Male fetus 249 (52.5) Female fetus 225 (47.5)
(14) Of the test subjects, 29 were carrying twins, and information thereof is shown in Table 2 below.
(15) TABLE-US-00002 TABLE 2 Characteristic Value No. of pregnant women 29 carrying twins Maternal age (year) Mean 35 Range 22 to 43 Gestational age (week) Mean 14 Median 13 Range 11 to 21 Pregnancy trimester (%) First: 1-13 week gestation 16 (55.2) Second: 14-26 week gestation 13 (44.8) Third: 27-40 week gestation 0 Fetal sex (%) Male fetus 26 (48.1) Female fetus 28 (51.9)
(16) Two pregnant women with unknown fetal sex were excluded.
(17) All 447 test subjects had amniocentesis for fetal karyotyping, the results of which were obtained by blind analysis. The institutional review board at each participating hospital approved this study. Written informed consent was obtained from all participants.
(18) All test subjects underwent standard prenatal aneuploidy screening in accredited clinical laboratories. First-trimester screening includes measurement of serum pregnancy-associated plasma protein A (PAPP-A), total or free beta subunit of human chorionic gonadotropin (hCG), and nuchal translucency. Second-trimester screening includes measurement of maternal serum alpha-fetoprotein (MSAFP), hCG, unconjugated estriol, and inhibin A.
(19) From the results of karyotyping, there were 13 fetuses with trisomy 21 (including three twin samples), one fetus with trisomy 18 in a twin pregnancy, one fetus with trisomy 13, and two fetuses with XXY. 17 samples with aneuploidy, 29 samples with twins, and 5 samples with higher GC contents were excluded from total 447 samples, and the remaining 396 samples were used as reference samples.
(20) 2. Preparation of Cell-Free DNA and DNA Libraries for DNA Sequencing
(21) About 10 mL of peripheral blood was collected from each test subject described in 1. in a BCT™ tube (Streck, Omaha, Nebr., USA). Each of the collected blood samples was centrifuged at 1,200×g at 4° C. for 15 min. The plasma portion of blood was collected and centrifuged again at 16,000×g at 4° C. for 10 min. Cell-free DNA (cfDNA) was extracted from the centrifuged plasma by using a QIAamp circulating nucleic acid kit (Qiagen, Netherland).
(22) The end-repair of the obtained cfDNA was carried out using T4 DNA polymerase, Klenow DNA polymerase, and T4 polynucleotide kinase, and then cfDNA fragments were obtained again by using Agencourt AMPure XP.
(23) DNA libraries for ion proton sequencing systems were constructed from the prepared cfDNA according to the protocol provided by the manufacturer (Life Technologies, S. Dak., USA). Proton PI Chip Kit version 2.0 was used to yield an average 0.3× sequencing coverage depth per nucleotide.
(24) 3. Massively Parallel Sequencing
(25) The DNA libraries prepared as in 2. were subjected to massively parallel sequencing by using ION PROTON™ system (Thermo Fisher Scientific).
(26) Different raw reads were obtained using ION TORRENT SUITE™ software (Thermo Fisher Scientific). The number of the obtained raw reads was about (7.4±2.1)×10.sup.6 per sample on average.
(27) The reads were trimmed from the 3′ end by sequencing, and low-quality reads were excluded from the subjects of analysis. Further, the reads were filtered by a quality threshold value of 20 and a read length threshold of 50 bp.
(28) The filtered reads were aligned to the human genomic reference sequences hg19 using Burrows-Wheeler transform (BWT). Sequence reads mapped to only one genome location in hg19 were termed unique reads. About 44.6% (about 3.3×10.sup.6) of the total reads were unique reads. The GC contents of the total 447 samples ranged from about 30% to about 60%.
(29) Meanwhile, duplicate DNA reads were removed from the subjects of analysis by Picard (http://picard.sourceforge.net/).
(30) 4. Correction and Normalization of DNA Reads
(31) In order to reduce the effect of GC bias in the DNA reads obtained in 3., and difference between samples, correction and normalization of the DNA reads were performed.
(32) First, all chromosomes were divided into segments with a bin size of 20 kb. The number of unique reads and GC content (rounded to 0.1%) in each bin were determined. Bins including reference sequences with undeterminable bases and bins without any reads were filtered.
(33) Then, a locally weighted scatterplot smoothing (LOESS) regression analysis was used. In detail, the fit predicted value (UR.sub.loess) of each bin was obtained by the number of unique reads (UR) in each bin against the GC content (GC.sub.bin) of the corresponding bin according to the following equation: UR.sub.loess=f(GC.sub.bin). The LOESS-corrected reads number (UR.sub.corrected) was calculated using the following equation: UR.sub.corrected=UR−[UR.sub.loess−e(UR)], wherein e(UR) was the expected value for unique reads of each bin, which was set to the overall average unique reads number in each bin (Liao C. et al., Proc. Natl. Acad. Sci., 2014, 111(20):7415-7420).
(34) After LOESS correction, a fraction of reads (Rf) of sample i on the chromosome j was calculated by the following equation:
Rf.sub.ij′=RC.sub.ij/Σ.sub.j=1.sup.22RC.sub.ij (Equation 1).
(35) In Equation 1, Rf.sub.ij′ represents a corrected fraction of reads on chromosome j in sample i, and RC.sub.ij represents a corrected number of unique reads on chromosome j in sample i.
(36) The normalized fraction of reads was calculated using the calculated Rf.sub.ij′ according to the following equation:
Rf.sub.i′j′=Rf.sub.ij′/Σ.sub.i=1.sup.NRf.sub.ij′ (Equation 2).
(37) In Equation 2, Rf.sub.i′j′ represents a normalized fraction of reads on chromosome j in sample i, and N represents the total number of samples.
(38) 5. Selection of Adaptive Reference Sample and Detection of Fetal Aneuploidy
(39) (1) Calculation of Z Scores for all Samples and Detection of Fetal Aneuploidy
(40) Fetal aneuploidy was detected in all samples according to a previous method of calculating z score.
(41) In detail, a full linear regression model for all samples was established, based on Rf.sub.i′j′=α+β×GC.sub.i′j′+e (Equation 3). A fitted predicted value of fraction of reads was calculated by the following equation: Rf′.sub.i′j′=α+β×GC.sub.i′j′ (Equation 4). In the above Equations, Rf.sub.i′j′ represents a normalized fraction of reads on chromosome j in sample i, Rf′.sub.i′j′ represents a fitted predicted value of fraction of reads on chromosome j in sample i, represents a GC content on chromosome j in sample i, β represents a coefficient factor between a GC content and Rf, a represents a constant, and e represents a residual (R). The residual (R) was calculated according to R=Rf.sub.i′j′−Rf′.sub.i′j′ (Equation 5); Equation 5, and fitted to a normal distribution. The z score for fetal aneuploidy was calculated by the following equation: z score=(R−R′)/σ′, wherein R represents a residual on the chromosome in the sample, R′ represents the average value of the residuals in reference samples or test samples, and σ′ represents the standard deviation of the residuals in reference samples or test samples. z score>3 represents a fraction of reads greater than that of the 99.9th percentile of the reference sample set.
(42) Z scores of the euploid samples and trisomy 21 (T21) of all samples are shown in
(43) (2) Detection of T21 Sample Using Adaptive Reference Sample
(44) It was considered that the ambiguous threshold in the previous method of detecting fetal aneuploidy as described in 5.(1) could result from a suboptimal reference sample collection. Therefore, reference samples adapted to a test sample were selected from the whole reference samples, followed by statistical analysis.
(45) First, GC contents of 13 positive samples (e.g., T21 sample) were examined. The positive samples were categorized into four groups according to GC content regions (ranging from −0.005 to +0.005). The two positive samples in the GC content region of 0.41, the five positive samples in the GC content region of 0.42, the two positive samples in the GC content region of 0.43, and the four positive samples in the GC content region of 0.44 were clustered according to the GC regions, respectively. Representative positive sample was selected from each group, and the selected positive sample was used to generate a set of adaptive reference samples by increasing the GC content by 0.001 and the reads fraction by 0.00005.
(46) As adaptive reference samples, reference samples belonging to a shared range of the GC content and Rf were extracted from all reference samples. The GC content range was set from −0.001 to +0.001 as a unit value when setting the GC content of a test sample as the median. The Rf was set from −0.00005 to +0.00005 as a unit value when setting the Rf of a test sample as the median, which was determined by the fitting predicted fraction of Rf calculated as Rf′.sub.i′j′=α+β×GC.sub.i′j′ (Equation 4) from all reference samples.
(47) A coefficient of variation (CV) was used to evaluate performance between the previous method of using whole reference samples and the method of using adaptive reference samples.
(48) (i) Application of Adaptive Selection Method to T21 Test Samples in GC Content Region of 0.41
(49) The coefficient of variation for chromosome 21 was calculated with and without adaptive sample selection using reference samples selected from a shared region of GC content 0.416±X and Rf linear predicted value±Y.
(50) In
(51) (A) to (F) of
(52) As shown in
(53) (ii) Application of Adaptive Selection Method to T21 Test Samples in GC Content Region of 0.42
(54) Similarly, of the five test samples in the GC content region of 0.42 of chromosome 21, samples in the GC content region of 0.424 of chromosome T21 were selected as a representative test sample, and other samples were used to demonstrate results using the adaptive reference samples. Six sets of reference samples (A, B, C, D, E, and F) were selected according to shared ranges of GC content and Rf based on the representative test samples (A: n=37, B: n=210, C: n=120, D: n=166, E: n=226, F: n=278), respectively. In
(55) (A) to (F) of
(56) Further, euploid samples arbitrarily selected in the GC content range of 0.424±0.001 were used as test samples, and the 6 sets of the reference samples were used to calculate z scores of the euploid test samples. As shown in
(57) (iii) Application of Adaptive Selection Method to T21 Test Samples in GC Content Region of 0.43
(58) Similarly, of the two test samples in the GC content region of 0.43 of chromosome 21, one sample in the GC content region of 0.437 of chromosome T21 was selected as a representative test sample, and the other sample was used to demonstrate results using the adaptive reference samples. Six sets of reference samples (A, B, C, D, E, and F) were selected according to shared ranges of GC content and Rf based on the representative test samples (A: n=31, B: n=90, C: n=138, D: n=189, E: n=227, F: n=292), respectively. In
(59) (A) to (F) of
(60) Further, euploid samples arbitrarily selected in the GC content range of 0.437±0.001 were used as test samples, and the 6 sets of the reference samples were used to calculate z scores of the euploid test samples. As shown in
(61) (iv) Application of Adaptive Selection Method to T21 Samples in GC Content Region of 0.44
(62) Similarly, of the four test samples in the GC content region of 0.44 of chromosome 21, samples in the GC content region of 0.446 of chromosome T21 were selected as representative test samples, and other samples were used to demonstrate results using the adaptive reference samples. Four sets of reference samples (A, B, C, and D) were selected according to shared ranges of GC content and Rf based on the representative test samples (A: n=38, B: n=127, C: n=93, D: n=181), respectively. In
(63) (A) to (D) of
(64) (3) Detection of T18 Sample Using Adaptive Reference Sample
(65) Trisomy 18 (T18) sample was detected by the adaptive selection method as described in 5.(2).
(66) Because there was only one T18 sample, a representative test sample was also used as a test sample. One set (A) of reference samples was selected according to a shared range of GC content and Rf based on the representative test sample (A: n=8). In
(67) In
(68) As shown in
(69) (4) Detection of T13 Sample Using Adaptive Reference Sample
(70) Trisomy 13 (T13) sample was detected by the adaptive selection method as described in 5.(2).
(71) Because there was only one T13 sample, a representative test sample was also used as a test sample. One set (A) of reference samples was selected according to a shared range of GC content and Rf based on the representative test sample (A: n=177). In
(72) In
(73) As shown in
(74) (5) Relationship of Fraction of Reads and GC Content in Chromosomes
(75) The relationship of a fraction of reads and a GC content in respective chromosomes was calculated by fitting to a linear model, and results are shown in
(76) As shown in
(77) Accordingly, whether a test sample is a trisomy fetus or not may be detected with excellent sensitivity and specificity by comparing Z scores calculated from selected reference samples and Z score calculated from the test sample.